Fareston(toremifene)
Fareston (toremifene) is a small molecule pharmaceutical. Toremifene was first approved as Fareston on 1996-02-14. It is used to treat breast neoplasms and hormone-dependent neoplasms in the USA. It has been approved in Europe to treat breast neoplasms.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Fareston (generic drugs available since 2018-12-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Toremifene citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FARESTON | Kyowa Kirin | N-020497 RX | 1997-05-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fareston | New Drug Application | 2020-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| hormone-dependent neoplasms | — | D009376 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hormone-dependent neoplasms | D009376 | — | — | 3 | — | — | 3 | ||
| Prostatic neoplasms | D011471 | C61 | — | 1 | 1 | — | — | 2 | |
| Prostatic intraepithelial neoplasia | D019048 | N42.31 | — | 1 | 1 | — | — | 2 | |
| Amenorrhea | D000568 | N91.2 | — | — | 1 | — | — | 1 | |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | 1 | — | — | 1 |
| Mastodynia | D059373 | EFO_1001366 | N64.4 | — | — | 1 | — | — | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 1 | — | — | 1 |
| Precancerous conditions | D011230 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Aggressive fibromatosis | D018222 | — | 1 | — | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TOREMIFENE |
| INN | toremifene |
| Description | Toremifene is a tertiary amine, an organochlorine compound and an aromatic ether. It has a role as an antineoplastic agent, an estrogen antagonist, an estrogen receptor modulator and a bone density conservation agent. It derives from a hydride of a stilbene. |
| Classification | Small molecule |
| Drug class | antiestrogens of the clomifene and tamoxifen groups |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 89778-26-7 |
| RxCUI | 38409 |
| ChEMBL ID | CHEMBL1655 |
| ChEBI ID | 9635 |
| PubChem CID | 3005573 |
| DrugBank | DB00539 |
| UNII ID | 7NFE54O27T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,117 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fareston
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,618 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more